295 related articles for article (PubMed ID: 32120017)
21. The Keap1-Nrf2 protein-protein interaction: A suitable target for small molecules.
Schmoll D; Engel CK; Glombik H
Drug Discov Today Technol; 2017 Jun; 24():11-17. PubMed ID: 29233294
[TBL] [Abstract][Full Text] [Related]
22. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.
Shibata T; Ohta T; Tong KI; Kokubu A; Odogawa R; Tsuta K; Asamura H; Yamamoto M; Hirohashi S
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13568-73. PubMed ID: 18757741
[TBL] [Abstract][Full Text] [Related]
23. Role of human Keap1 S53 and S293 residues in modulating the binding of Keap1 to Nrf2.
Wei S; Pei Y; Wang Y; Guan H; Huang Y; Xing T; Johnson RW; Wang D
Biochimie; 2019 Mar; 158():73-81. PubMed ID: 30576774
[TBL] [Abstract][Full Text] [Related]
24. Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation Spectroscopy.
Yoshizaki Y; Mori T; Ishigami-Yuasa M; Kikuchi E; Takahashi D; Zeniya M; Nomura N; Mori Y; Araki Y; Ando F; Mandai S; Kasagi Y; Arai Y; Sasaki E; Yoshida S; Kagechika H; Rai T; Uchida S; Sohara E
Sci Rep; 2017 Jun; 7(1):3945. PubMed ID: 28638054
[TBL] [Abstract][Full Text] [Related]
25. Molecular recognition between potential natural inhibitors of the Keap1-Nrf2 complex.
Bello M; Morales-González JA
Int J Biol Macromol; 2017 Dec; 105(Pt 1):981-992. PubMed ID: 28746889
[TBL] [Abstract][Full Text] [Related]
26. The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway.
Baird L; Yamamoto M
Mol Cell Biol; 2020 Jun; 40(13):. PubMed ID: 32284348
[TBL] [Abstract][Full Text] [Related]
27. Structural basis of Keap1 interactions with Nrf2.
Canning P; Sorrell FJ; Bullock AN
Free Radic Biol Med; 2015 Nov; 88(Pt B):101-107. PubMed ID: 26057936
[TBL] [Abstract][Full Text] [Related]
28. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex.
McMahon M; Thomas N; Itoh K; Yamamoto M; Hayes JD
J Biol Chem; 2006 Aug; 281(34):24756-68. PubMed ID: 16790436
[TBL] [Abstract][Full Text] [Related]
29. p97 Negatively Regulates NRF2 by Extracting Ubiquitylated NRF2 from the KEAP1-CUL3 E3 Complex.
Tao S; Liu P; Luo G; Rojo de la Vega M; Chen H; Wu T; Tillotson J; Chapman E; Zhang DD
Mol Cell Biol; 2017 Apr; 37(8):. PubMed ID: 28115426
[TBL] [Abstract][Full Text] [Related]
30. Investigation of Molecular Details of Keap1-Nrf2 Inhibitors Using Molecular Dynamics and Umbrella Sampling Techniques.
Londhe AM; Gadhe CG; Lim SM; Pae AN
Molecules; 2019 Nov; 24(22):. PubMed ID: 31726716
[TBL] [Abstract][Full Text] [Related]
31. KEAP1, a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease.
Dayalan Naidu S; Dinkova-Kostova AT
Open Biol; 2020 Jun; 10(6):200105. PubMed ID: 32574549
[TBL] [Abstract][Full Text] [Related]
32. The Keap1-Nrf2 system as an in vivo sensor for electrophiles.
Uruno A; Motohashi H
Nitric Oxide; 2011 Aug; 25(2):153-60. PubMed ID: 21385624
[TBL] [Abstract][Full Text] [Related]
33. Molecular Basis of the KEAP1-NRF2 Signaling Pathway.
Suzuki T; Takahashi J; Yamamoto M
Mol Cells; 2023 Mar; 46(3):133-141. PubMed ID: 36994473
[TBL] [Abstract][Full Text] [Related]
34. Molecular basis for the disruption of Keap1-Nrf2 interaction via Hinge & Latch mechanism.
Horie Y; Suzuki T; Inoue J; Iso T; Wells G; Moore TW; Mizushima T; Dinkova-Kostova AT; Kasai T; Kamei T; Koshiba S; Yamamoto M
Commun Biol; 2021 May; 4(1):576. PubMed ID: 33990683
[TBL] [Abstract][Full Text] [Related]
35. Sp1 is a substrate of Keap1 and regulates the activity of CRL4A
Siswanto FM; Oguro A; Imaoka S
J Biol Chem; 2021; 296():100704. PubMed ID: 33895141
[TBL] [Abstract][Full Text] [Related]
36. Pterostilbene-mediated Nrf2 activation: Mechanistic insights on Keap1:Nrf2 interface.
Bhakkiyalakshmi E; Dineshkumar K; Karthik S; Sireesh D; Hopper W; Paulmurugan R; Ramkumar KM
Bioorg Med Chem; 2016 Aug; 24(16):3378-86. PubMed ID: 27312421
[TBL] [Abstract][Full Text] [Related]
37. Replacement of a Naphthalene Scaffold in Kelch-like ECH-Associated Protein 1 (KEAP1)/Nuclear Factor (Erythroid-derived 2)-like 2 (NRF2) Inhibitors.
Richardson BG; Jain AD; Potteti HR; Lazzara PR; David BP; Tamatam CR; Choma E; Skowron K; Dye K; Siddiqui Z; Wang YT; Krunic A; Reddy SP; Moore TW
J Med Chem; 2018 Sep; 61(17):8029-8047. PubMed ID: 30122040
[TBL] [Abstract][Full Text] [Related]
38. Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor.
Yasuda D; Yuasa A; Obata R; Nakajima M; Takahashi K; Ohe T; Ichimura Y; Komatsu M; Yamamoto M; Imamura R; Kojima H; Okabe T; Nagano T; Mashino T
Bioorg Med Chem Lett; 2017 Nov; 27(22):5006-5009. PubMed ID: 29037947
[TBL] [Abstract][Full Text] [Related]
39. Characterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 binding.
Huerta C; Jiang X; Trevino I; Bender CF; Ferguson DA; Probst B; Swinger KK; Stoll VS; Thomas PJ; Dulubova I; Visnick M; Wigley WC
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2537-2552. PubMed ID: 27474998
[TBL] [Abstract][Full Text] [Related]
40. Advances in developing noncovalent small molecules targeting Keap1.
Barreca M; Qin Y; Cadot MEH; Barraja P; Bach A
Drug Discov Today; 2023 Dec; 28(12):103800. PubMed ID: 37852355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
